Brief: Mezzion Pharma Submits Protocol For Confirmatory Pivotal Phase 3 Trial
21/02/2023 14:10
Feb 21 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ :
* MEZZION PHARMA SUBMITS PROTOCOL FOR CONFIRMATORY PIVOTAL
PHASE 3
TRIAL ("FUEL-2") IN FONTAN SUBJECTS
* MEZZION PHARMA CO LTD - IN TYPE B MEETING, AN AGREEMENT
WAS
REACHED WITH FDA REGARDING ITS REQUIREMENT FOR A CONFIRMATORY
PHASE 3 CLINICAL TRIAL
* MEZZION PHARMA CO LTD - PHASE 3 FUEL-2 STUDY ENROLLMENT IS
EXPECTED TO BE INITIATED WITHIN NEXT FEW WEEKS
Source text for Eikon: ID:nPnCkgRZa
Further company coverage: 140410.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2